11/5/2026

speaker
Conference Operator
Operator

Good morning and welcome to the Novavax third quarter 2026 financial results and operational highlights conference call. All participants will be in a listen-only mode. Should you need any assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then the number 1 on your telephone keypad. To withdraw your question, simply press star 1 again. Please note, this event is being recorded. I would now like to turn the conference over to Jim Kelly, Executive Vice President and Chief Financial Officer. Please go ahead.

speaker
Naina
Investor Relations

Good morning and thank you for joining us today to discuss our third quarter financial results and operational highlights today on November 5th, 2026. A press release announcing our results is available on our website at www.novavax.com and an audio archive of this conference call will be available on our website later today. Before we begin with our prepared remarks, I would like to remind you that this presentation includes forward-looking statements regarding Novavax's current expectations related to, but not limited to, its partnerships, market opportunities, and financial guidance. Our actual results may be materially different from such statements as detailed in the presentation. Discussions of non-GAAP figures and reconciliations to GAAP figures are available in our earnings press release and presentation. Descriptions of the risks and uncertainties associated with Novavax are included in our SEC filings. These can be accessed through our website. Joining me today are John Jacobs, our President and CEO, Elaine O'Hara, Chief Strategy Officer, Dr. Bob Walker, Head of R&D, and Jim Kelly, our Chief Financial Officer. I would now like to hand the call over to John.

speaker
John Jacobs
President and Chief Executive Officer

Thank you, Naina, and welcome, everyone. As we near the end of 2026, I'm pleased with the progress we have made this year across the three pillars of our strategy, partnering our vaccine technology, driving targeted and capital-efficient R&D innovation, and maintaining a lean and agile operating model. For those new to our story, Novavax is a vaccine technology company focused on creating long-term value through partnerships. We believe our technology can underpin a broad range of vaccines in infectious disease, from viral to bacterial, and we are in the early stages of exploring its potential in oncology. By combining our own innovation with that of our partners and leveraging their manufacturing scale and commercial reach, we aim to expand access to our technology, unlock new opportunities, and build a legacy of lasting impact on global health. Our technology platform is the engine behind our business, built on a proven foundation in infectious disease. Today, it is used in two commercial vaccines, Nuvaxavid for COVID-19 and R21 Matrix-M for malaria. Both have demonstrated protection against serious disease and favorable tolerability at population scale, with R21 Matrix-M extending that impact to children as young as five months old in malaria-endemic regions. Our technology is also being applied in some of the most attractive vaccine markets. Sanofi recently initiated its Phase 3 influenza COVID-19 combination vaccine trial in Europe, and Sanofi management confirmed to us that they are targeting a U.S. Phase 3 start in 2027 to support U.S. approval. The trial in Europe utilizes Novavax's differentiated COVID-19 vaccine and Sanofi's market-leading Fluzone high-dose influenza vaccine. The initiation of the phase three kick trial triggered a one-time $125 million milestone to Novavax and represents a significant future opportunity. This opens up even greater potential with the global flu and COVID-19 markets having a current combined value that exceeds $10 billion with significant burden of disease. Beyond viral diseases, we intend to enter the clinic with our differentiated C. diff vaccine candidate as early as next year. With no approved vaccine today, C. diff accounts for roughly half a million cases and over 20,000 in-hospital deaths annually in the US alone. This represents a significant unmet medical need and an opportunity for our technology to help millions of people in what could become a large and significant vaccine market. Vaccine innovation has always been at the core of Novavax. We are already an established vaccine technology company and we plan to expand further in infectious disease with our partners and MTA collaborators while advancing our early work in oncology by bringing in new partners, deepening existing partnerships and potentially enabling new vaccines. We see significant opportunities for our technology to drive long-term value creation. Now let's take a few moments to touch upon some of the progress we have made over the past few months on the three pillars of our strategy. Starting with pillar one, partnering our vaccine technology. As already noted, Novavax earned a $125 million milestone following the initiation of Sanofi's pivotal phase three kick trial in Europe last month. We are on track to earn an additional $75 million milestone upon the completion of Sanofi's manufacturing technology transfer in mid-2027. Sanofi kicked off the 26-27 COVID season with Novavaxavid in the U.S., supported by expanded promotional efforts. They also introduced Nuvaccidid in select international markets, while Takeda continues to successfully promote the vaccine in Japan. We're pleased at the level of collaboration with Pfizer and look forward to continued progress on that front, with the potential to share more about the opportunities ahead as that partnership continues to evolve. And our MTA collaborations continue to advance, with interest from companies and organizations in exploring our technology across a broad range of disease areas. Elaine will elaborate further on our progress within this pillar in a few moments. And now pillar two, targeted and capital efficient R&D innovation. Our work in R&D at Novavax focuses on three objectives. First, building a library of data to better understand how and where our existing technology can have an impact. Second, expanding the utility of our MatrixM technology platform. And third, advancing select innovative vaccine candidates. We're pleased with our progress in all three of these areas to date, and Bob will elaborate further during his commentary today. And finally, pillar three, lean and agile operating model. Underpinning all of this is our financial discipline. This quarter, we raised our full-year revenue framework and improved our expense guidance, bringing more clarity to our outlook. We continue to drive down costs while maintaining core capabilities that we believe are critical to enable the successful execution of our strategy. Jim will take you through our performance and updated guidance later in the call. In closing, we're building a growing set of opportunities with existing partners, potential new partners, and from our own platform across infectious disease and potentially oncology. Over time, it is our vision to see our technology embedded in a diversified set of commercial vaccines and development programs with multiple partners. And with that, I will turn the call over to Elaine to provide an update on our partnership efforts. Elaine?

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation